ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies

@article{Nicholls2012ApoAIIA,
  title={ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies},
  author={Stephen J. Nicholls and Allan Gordon and Jan Johannson and Christie M. Ballantyne and Philip John Barter and H. Bryan Jr. Brewer and John J. P. Kastelein and Norman C. W. Wong and Marilyn Borgman and Steven E Nissen},
  journal={Cardiovascular Drugs and Therapy},
  year={2012},
  volume={26},
  pages={181-187}
}
BackgroundConsiderable interest has focused on the development of therapies that target the functionality of high-density lipoproteins (HDL). Upregulation of endogenous synthesis of the major protein on HDL particles, apolipoprotein A-I (apoA-I), represents a novel approach to generation of new HDL particles. The Study of Quantitative Serial Trends in Lipids with Apolipoprotein A-I Stimulation (SUSTAIN, NCT01423188) study aims to evaluate the lipid efficacy, safety and tolerability of an apoA-I… 
An evaluation of RVX-208 for the treatment of atherosclerosis
TLDR
The current evidence suggests promising beneficial effects of this novel drug in the prevention and treatment of atherosclerosis and other metabolic disorders and a shift in particle size to larger HDL particles, which may have potent atheroprotective effects.
HDL, Atherosclerosis, and Emerging Therapies
TLDR
This review aims to provide an overview on the properties of high-density lipoproteins (HDLs) and their cardioprotective effects and to focus on novel therapeutic avenues and potential biomarkers of HDL function.
Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond
TLDR
A number of pharmacological strategies that target apoA-I, including upregulation of its production with the bromodomain and extraterminal (BET) protein inhibitor RVX-208, development of short peptide sequences that mimic its action, and administration as a component of reconstituted HDL particles, have undergone clinical development and the impact of these approaches on cardiovascular biomarkers will be reviewed.
Pharmacological interventions in human HDL metabolism
TLDR
In the poststatin era, personalized medicine, which is inevitably on the horizon, is likely to be helpful for patients who do not reach the goals for LDL cholesterol and HDL-c according to the guidelines, and functions of HDL will hopefully be identified as future pharmacological targets.
Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial
TLDR
Administration of the BET protein inhibitor RVX-208 showed no greater increase in apoA-I or HDL-C or incremental regression of atherosclerosis than administration of placebo.
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
TLDR
Overall, data showed that RVX-208 raises ApoA-I/HDL and represses pro-inflammatory, pro-atherosclerotic and pro-thrombotic pathways that can contribute to CVD risk.
HDL-targeted therapies: progress, failures and future
TLDR
The HDL hypothesis is examined in molecular and mechanistic terms, focusing on features that have been addressed, those that remain to be tested, and potential new targets for future pharmacological interventions.
Targeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance
TLDR
It is suggested that fibrates have consistently reduced some cardiovascular outcomes, at least in the subgroup of patients with high serum triglycerides and low HDL cholesterol (HDLc) levels.
From Lipids to Inflammation : New Approaches to Reducing Atherosclerotic Risk
Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.115.306471 Abstract: The introduction of statins ≈30 years ago ushered in the era of lipid lowering as the
From Lipids to Inflammation
Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.115.306471 Abstract: The introduction of statins ≈30 years ago ushered in the era of lipid lowering as the
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
TLDR
Administration of RVX-208 for 12 weeks was associated with increases in apoA-I, HDL-C, and concentration of large HDL particles, consistent with facilitation of cholesterol mobilization, suggesting that peak pharmacological effect has not been achieved by the end of the 12-week study.
RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.
TLDR
Data in humans point to beneficial features of RVX-208 that might be useful for treating atherosclerosis, and changes were not mediated by cholesteryl-ester-transfer protein.
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
TLDR
For patients with coronary disease, treatment with an ACAT inhibitor did not improve the primary efficacy variable (percent atheroma volume) and adversely affected two major secondary efficacy measures assessed by intravascular ultrasonography.
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
TLDR
Compared with placebo or statin monotherapy, evacetrapib as monotherapy or in combination with statins increased HDL-C levels and decreased LDL-C Levels, and the effects on cardiovascular outcomes require further investigation.
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.
TLDR
A recombinant ApoA-I Milano/phospholipid complex administered intravenously for 5 doses at weekly intervals produced significant regression of coronary atherosclerosis as measured by IVUS, and results require confirmation in larger clinical trials with morbidity and mortality end points.
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.
TLDR
Short-term infusions of reconstituted HDL resulted in no significant reductions in percentage change in atheroma volume or nominal change in plaque volume compared with placebo but did result in statistically significant improvement in the plaque characterization index and coronary score on quantitative coronary angiography.
The failure of torcetrapib: was it the molecule or the mechanism?
TLDR
This study was designed to determine the clinical outcome of raising HDL by treatment with the CETP inhibitor torcetrapib in combination with atorvastatin, and was terminated abruptly and unexpectedly after a little more than a year of treatment.
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
TLDR
Dal-OUTCOMES will determine whether CETP inhibition with dalcetrapib, added to current evidence-based care, reduces cardiovascular morbidity and mortality after ACS.
Antiinflammatory Properties of HDL
There are several well-documented functions of high-density lipoprotein (HDL) that may explain the ability of these lipoproteins to protect against atherosclerosis. The best recognized of these is
Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits
TLDR
Infusing small amounts of HDL rapidly reduces lesion size and is comparable to atorvastatin in promoting a stable plaque phenotype and the beneficial effects on lesion area and plaque cellular composition were influenced by HDL phospholipid and apolipoprotein composition.
...
1
2
3
4
5
...